Jump to content

Catechol-O-methyltransferase inhibitor: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Citation bot (talk | contribs)
Bots
5,407,073 edits
Add: s2cid, issue, year, authors 1-1. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Headbomb | Linked from Wikipedia:WikiProject_Academic_Journals/Journals_cited_by_Wikipedia/Sandbox | #UCB_webform_linked 81/499
Line 10: Line 10:
* [[tolcapone]] (Tasmar)
* [[tolcapone]] (Tasmar)


Entacapone and opicapone are peripheral inhibitors, unable to cross the [[Blood–brain barrier|blood-brain barrier]]. Tolcapone is able to cross the blood-brain barrier.<ref>{{Cite journal|last1=Lang|first1=Anthony E.|last2=Connolly|first2=Barbara S.|date=2014-04-23|title=Pharmacological Treatment of Parkinson Disease: A Review|journal=JAMA|language=en|volume=311|issue=16|pages=1670–1683|doi=10.1001/jama.2014.3654|pmid=24756517|issn=0098-7484}}</ref> Tolcapone has been associated with at least three fatal cases of [[acute liver failure]] and is thus only rarely prescribed.<ref>{{Cite journal|last1=Olanow|first1=C. Warren|last2=Watkins|first2=Paul B.|date=Sep 2007|title=Tolcapone: an efficacy and safety review|journal=Clinical Neuropharmacology|volume=30|issue=5|pages=287–294|doi=10.1097/wnf.0b013e318038d2b6|issn=0362-5664|pmid=17909307|s2cid=19148461}}</ref> Patients taking tolcapone must be monitored for hepatic failure. Entacapone and opicapone have not been associated with hepatotoxicity.<ref>{{Cite journal|last=Scott|first=Lesley J.|date=2016-08-06|title=Opicapone: A Review in Parkinson's Disease|journal=Drugs|volume=76|issue=13|pages=1293–1300|doi=10.1007/s40265-016-0623-y|pmid=27498199|s2cid=5787752|issn=0012-6667}}</ref><ref>{{Cite journal|last=Watkins|first=P|title=COMT inhibitors and liver toxicity|journal=Neurology|volume=55 (11 Suppl 4)|pages=S51-2|pmid=11147510}}</ref>
Entacapone and opicapone are peripheral inhibitors, unable to cross the [[Blood–brain barrier|blood-brain barrier]]. Tolcapone is able to cross the blood-brain barrier.<ref>{{Cite journal|last1=Lang|first1=Anthony E.|last2=Connolly|first2=Barbara S.|date=2014-04-23|title=Pharmacological Treatment of Parkinson Disease: A Review|journal=JAMA|language=en|volume=311|issue=16|pages=1670–1683|doi=10.1001/jama.2014.3654|pmid=24756517|issn=0098-7484}}</ref> Tolcapone has been associated with at least three fatal cases of [[acute liver failure]] and is thus only rarely prescribed.<ref>{{Cite journal|last1=Olanow|first1=C. Warren|last2=Watkins|first2=Paul B.|date=Sep 2007|title=Tolcapone: an efficacy and safety review|journal=Clinical Neuropharmacology|volume=30|issue=5|pages=287–294|doi=10.1097/wnf.0b013e318038d2b6|issn=0362-5664|pmid=17909307|s2cid=19148461}}</ref> Patients taking tolcapone must be monitored for hepatic failure. Entacapone and opicapone have not been associated with hepatotoxicity.<ref>{{Cite journal|last=Scott|first=Lesley J.|date=2016-08-06|title=Opicapone: A Review in Parkinson's Disease|journal=Drugs|volume=76|issue=13|pages=1293–1300|doi=10.1007/s40265-016-0623-y|pmid=27498199|s2cid=5787752|issn=0012-6667}}</ref><ref>{{Cite journal|last=Watkins|first=P|title=COMT inhibitors and liver toxicity|journal=Neurology|year=2000|volume=55 (11 Suppl 4)|issue=11 Suppl 4|pages=S51-2|pmid=11147510}}</ref>


== Adverse effects ==
== Adverse effects ==
Line 37: Line 37:
{{Reflist}}
{{Reflist}}


<ref>{{Cite journal|last=Govindasamy|first=Hunday|last2=Magudeeswaran|first2=Sivanandam|last3=Poomani|first3=Kumaradhas|date=2020-12-11|title=Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics/molecular mechanics and molecular dynamics simulations|url=https://doi.org/10.1080/07391102.2019.1699446|journal=Journal of Biomolecular Structure and Dynamics|volume=38|issue=18|pages=5307–5319|doi=10.1080/07391102.2019.1699446|issn=0739-1102|pmid=31779524}}</ref>
<ref>{{Cite journal|last1=Govindasamy|first1=Hunday|last2=Magudeeswaran|first2=Sivanandam|last3=Poomani|first3=Kumaradhas|date=2020-12-11|title=Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics/molecular mechanics and molecular dynamics simulations|url=https://doi.org/10.1080/07391102.2019.1699446|journal=Journal of Biomolecular Structure and Dynamics|volume=38|issue=18|pages=5307–5319|doi=10.1080/07391102.2019.1699446|issn=0739-1102|pmid=31779524|s2cid=208356889}}</ref>
{{Enzyme inhibition}}
{{Enzyme inhibition}}
{{Antiparkinson}}
{{Antiparkinson}}

Revision as of 19:54, 29 December 2021

Metabolism of levodopa by catechol-O-methyltransferase (COMT) and aromatic L-amino acid decarboxylase (AADC). COMT inhibitors prevent the conversion of levodopa to 3-O-methyldopa.

A catechol-O-methyltransferase (COMT) inhibitor is a drug that inhibits the enzyme catechol-O-methyltransferase. This enzyme methylates catecholamines such as dopamine, norepinephrine and epinephrine. It also methylates levodopa. COMT inhibitors are indicated for the treatment of Parkinson's disease in combination with levodopa and an aromatic L-amino acid decarboxylase inhibitor (e.g. carbidopa or benserazide). The therapeutic benefit of using a COMT inhibitor is based on its ability to prevent the methylation of levodopa to 3-O-methyldopa, thus increasing the bioavailability of levodopa. COMT inhibitors significantly decrease off time in people with Parkinson's disease also taking carbidopa/levodopa.[1]

List of COMT inhibitors

Entacapone and opicapone are peripheral inhibitors, unable to cross the blood-brain barrier. Tolcapone is able to cross the blood-brain barrier.[2] Tolcapone has been associated with at least three fatal cases of acute liver failure and is thus only rarely prescribed.[3] Patients taking tolcapone must be monitored for hepatic failure. Entacapone and opicapone have not been associated with hepatotoxicity.[4][5]

Adverse effects

  • nausea
  • orthostatic hypotension
  • vivid dreams
  • confusion
  • hallucinations
  • hepatotoxicity (only tolcapone)
  • diarrhea
  • drowsiness
  • urine discoloration
  • dyskinesia

See also

References

  1. ^ "Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group". Annals of Neurology. 42 (5): 747–755. Nov 1997. doi:10.1002/ana.410420511. ISSN 0364-5134. PMID 9392574. S2CID 975995.
  2. ^ Lang, Anthony E.; Connolly, Barbara S. (2014-04-23). "Pharmacological Treatment of Parkinson Disease: A Review". JAMA. 311 (16): 1670–1683. doi:10.1001/jama.2014.3654. ISSN 0098-7484. PMID 24756517.
  3. ^ Olanow, C. Warren; Watkins, Paul B. (Sep 2007). "Tolcapone: an efficacy and safety review". Clinical Neuropharmacology. 30 (5): 287–294. doi:10.1097/wnf.0b013e318038d2b6. ISSN 0362-5664. PMID 17909307. S2CID 19148461.
  4. ^ Scott, Lesley J. (2016-08-06). "Opicapone: A Review in Parkinson's Disease". Drugs. 76 (13): 1293–1300. doi:10.1007/s40265-016-0623-y. ISSN 0012-6667. PMID 27498199. S2CID 5787752.
  5. ^ Watkins, P (2000). "COMT inhibitors and liver toxicity". Neurology. 55 (11 Suppl 4) (11 Suppl 4): S51-2. PMID 11147510.

[1]


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  1. ^ Govindasamy, Hunday; Magudeeswaran, Sivanandam; Poomani, Kumaradhas (2020-12-11). "Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics/molecular mechanics and molecular dynamics simulations". Journal of Biomolecular Structure and Dynamics. 38 (18): 5307–5319. doi:10.1080/07391102.2019.1699446. ISSN 0739-1102. PMID 31779524. S2CID 208356889.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Catechol-O-methyltransferase_inhibitor&oldid=1062660246"